דינמיקת הכנסות משנה לשנה ב-12 החודשים האחרונים: Silence Therapeutics Corp (SLN)

Despite liquidity shortages and the depletion of reserves, Silence Therapeutics (SLN) maintains its status as a reputable British pioneer in RNA therapeutics. The sales dynamics over the last 12 months year-over-year demonstrate a current trend where the value of 0.00 reflects the metric's balance. The company's high scientific potential is based on the creation of siRNA molecules for the targeted suppression of genetic defects in rare pathologies.
silence-therapeutics.com - פילוחים אנליטיים ומדדי מפתח (SLN)

For Silence Therapeutics (SLN), revenue dynamics from strategic alliances in the siRNA drug sector directly determine the pace of innovation commercialization. By analyzing revenue volatility compared to the same period last year on a TTM basis, an investor assesses the percentage deviation of the current aggregate 12-month income from the previous year's value, which reveals the actual business scaling speed and the risks of excessive capital freeze.